Press Releases Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 07/05/2026 BST			5-day change	1st Jan Change
6.370 ^USD	-0.93%		-1.70%	-55.86%

04-28	Quoin Pharmaceuticals provides clinical and regulatory update for QRX009 topical rapamycin development programs	RE
04-28	Quoin Pharmaceuticals Ltd Provides Clinical And Regulatory Update For QRX009 Topical Rapamycin Development Programs	CI

Press Releases

05-07	Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results	AQ
04-30	Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026	AQ
04-28	Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs	AQ
03-26	Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results	AQ
03-25	Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome	AQ
03-19	Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026	AQ
03-11	Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome	AQ
02-26	NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome	AQ
01-27	Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome	AQ
01-20	Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome	GL
11-11	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	AQ
11-06	Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results	AQ
30/10/25	Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025	AQ
28/10/25	Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study	AQ
21/10/25	Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome	AQ
13/10/25	Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million	AQ
10/10/25	Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million	AQ
09/09/25	Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome	AQ
21/08/25	Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome	AQ
18/08/25	Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy	AQ
12/08/25	Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton	AQ
07/08/25	Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update	AQ
31/07/25	Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025	AQ
29/07/25	Quoin Pharmaceuticals Provides Product Portfolio Update	AQ
26/06/25	Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases	AQ